The objective of the study was to investigate the utility of 24 h ambulatory blood pressure measurement (ABPM) in patients with chronic renal disease (CRD). A retrospective audit was performed in an academic nephrology department. ABPMs obtained from 95 consecutive outpatients with nondiabetic renal disease were analysed for their power to stratify disease severity and to predict progression of renal insufficiency during 3 years follow-up. The average of 10 consecutive office blood pressure (BP) readings performed at baseline was used as a reference. Correlations and tabulated statistics were calculated. Baseline mean diurnal BP was 138/ 87 mmHg by ABPM and 146/92 mmHg by average office BP (56.8 vs 25.3% normotensives, Po0.01). Mean serum creatinine was 1547109 lmol/l. Patients without a circadian BP pattern (61%) had significantly higher serum creatinine, urinary albumin excretion and subsequent progression rates of renal failure (Po0.05). Systolic and pulse pressure ABP values correlated significantly with serum creatinine levels at baseline and 3 years thereafter, independent of daytime (r ¼ 0.23-0.60; Po0.05). Abnormal nocturnal systolic and mean ABP, and pulse pressure but not average day office BP were significantly associated with abnormal serum creatinine and the presence of coronary heart disease at baseline (relative risk 1.6-1.7, Po0.05). In conclusion, physicians considered ABPM preferentially in patients with borderline-controlled BP. ABPM provided significant additional information relevant to the clinical decision making process compared with average office BP alone thereby justifying its use in specific situations.
Introduction
Hypertension is common in patients with chronic renal disease (CRD) and its prevalence has been reported between 60 and 100%, depending on the population studied. 1 In these patients, elevated blood pressure (BP) is a strong risk factor for the decline of renal function and the risk directly correlates with BP levels. Adequate BP control, therefore, remains a primary therapeutic goal to prevent rapid progression towards end-stage renal failure. 2 Physicians have traditionally relied on office BP measurements to manage hypertension. Nevertheless, 24 h ambulatory blood pressure measurement (ABPM) represents an attractive alternative to assess BP levels and to guide antihypertensive therapy.
ABPM clearly provides a more comprehensive picture of an individual's BP than casual office BP readings. Furthermore, the prediction of outcome and risk has been shown to be more accurate by ABPM than by office BP measurements in many circumstances. [3] [4] [5] [6] In clinical routine practice, however, the decision to use ABPM as a test still largely depends on the physician's personal judgement and preferences. 7 Patients with CRD who undergo ABPM are not well characterised and the routine use of ABPM in these patients still lacks comprehensive evidence. In this context, a recent expert review of hypertension in CRD concluded that ABPM should be used more critically because its advantages compared with office BP measurements still remain unclear. 8 Additionally, ABPM's superiority demonstrated usually in homogeneous study populations with essential hypertension might not necessarily apply to patients with CRD seen in a routine clinical setting. To address these questions, we performed a retrospective survey in patients with nonend-stage CRD attending our outpatients' department who had had an ABPM during their clinical work-up. An audit was designed. To assess clinical utility, we compared ABPM's predictive values with that of a series of office BP measurements performed at the same time. We tested the hypothesis that ABPM was associated with the severity and progression of CRD coronary heart disease (CHD) while adding useful clinical information to office BP measurements alone.
Methodology
We interrogated our clinical database. A total of 6116 patients attending our renal outpatients clinic in 1995 and 1996 were screened for the presence of CRD as indicated by a renal diagnosis and a 24 h ABPM. Patients with end-stage renal disease (serum creatinine 4500 mmol/l), diabetes mellitus of any type, severe congestive heart failure (NYHA class IV), primary endocrine disorders, renal transplants, pregnancy or metastatic malignant disease were excluded. Furthermore, patients were also excluded who had repeated ABPM during follow-up to control for an unbiased conclusion, and those lost to follow-up. The hospital's renal outpatient unit continuously receives patients from the whole region. At the clinic, ABPM was limited to those patients residing in the hospital's vicinity. Others were asked to have their ABPM performed locally by their referring physicians who then reported their results to the clinic by written statements. Since validity and accuracy of these reports could not be checked, we decided not to use this source of information. In all, 95 patients finally were eligible and entered analysis. The diagnosis of CRD had been confirmed by a biopsy with ultrasound and/or radiographic imaging studies.
ABPM was with a SpaceLabs (USA) 90239A monitor according to established guidelines and standards. 9 The time interval between measurements was 20 min during daytime and 30 min during nighttime. Mean arterial pressure (MAP), mean day or mean night systolic and diastolic blood pressures (SBP, DBP) and pulse pressure (PP) were calculated. To compare ABPM results with conventional BP readings, casual office BPs obtained during the first 10 visits following ABPM were averaged and served as a reference. Serum creatinine (CREA) concentrations, 24-h albumin excretion (UAE) and clinical chemistry parameters at the time of ABPM were obtained; CREA values were also obtained after 3 years. Patients with a day to night MAP ratio p0.9 were classified as dippers (DIP) and otherwise as nondippers (non-DIP).
During the study period, all patients received antihypertensive medication in accordance with international guidelines and a strict BP goal of o140/90 mmHg. 10 
Results
The patients' characteristics are shown in Table 1 . In all, 36% were female. The most frequent diagnoses were glomerulonephritis, chronic interstitial nephritis and ischaemic or hypertensive nephropathy. The patients' mean duration of hypertension was 15 years and all had antihypertensive treatment. A total ). There were no significant differences, when DIPs and non-DIPs were compared separately (P ¼ NS, data not shown).
The results for clinical chemistry and body mass index are shown in Table 2 . At baseline, the average CREA of all patients included was abnormal and there was significant albuminuria. DIP and non-DIP patients did not show differences in their characteristics except for HDL cholesterol. CREA at baseline correlated with CREA after 3 years (r ¼ 0.77, Po0.05). During follow-up, average CREA steadily increased by 18.9% (Po0.05). The increase was greater in non-DIPs (24.4%, Po0.05) compared with DIPs who showed no significant change with time. The characteristic of dipper status was independent of the presence or absence of hypertension at baseline. However, CREA increased more rapidly in hypertensive compared with normotensive nonDIPs (Po0.05; data not shown). Baseline UAE was significantly higher in non-DIPs compared with DIPs but the difference was lost after 3 years. Table 3 shows baseline ABPM and average office BP according to dipper status. Average office BP was significantly higher than diurnal ABP results (Po0.01), by 5-8 mmHg. Average systolic and diastolic office BP correlated with ABPM (r ¼ 0.46- Table 2 Serum values, urinary albumin excretion and body mass index of the patients, and in dippers compared with non-dippers Table 4 gives the association of baseline ABPM and average office BP with CREA according to time of CREA sampling. Day and night ambulatory SBP, PP and night MAP correlated significantly with CREA at baseline and after 3 years (Po0.05). Similarly, the day/night MAP ratio correlated also with CREA at baseline. The correlations were also present when normotensive or hypertensive patients were analysed separately (data not shown). In contrast, average office BP did not correlate with CREA. Odds ratios for abnormal night ambulatory SBP or MAP and CREA were 44.0, RR was 1.6-1.7 and LHR were between 3 and 4 (Po0.05). Diurnal ABP results and average office BP showed no such associations albeit there was a trend. UAE correlated only with baseline diastolic ABP results (r ¼ 0.20, Po0.05). Furthermore, abnormal BP results and high-grade UAE were not associated (P ¼ NS, data not shown). Table 5 shows the associations of BP with coronary heart disease. Night systolic and mean arterial ABPM values were significantly linked with a history of CHD (OR43, Po0.05) while average office BP was not. The sensitivity of these parameters was between 54 and 68%.
Discussion
As a main finding, selected ABPM parameters correlated significantly with CREA levels at baseline and after 3 years. The correlations were clinically relevant since linear regression slopes were not negligible and correlations were reproducible during follw-up. Furthermore, non-DIP status was significantly associated with renal disease severity and the decline of renal function. When a stratified risk model was applied based on normal and abnormal results, only nocturnal SBP and MAP were significantly associated with renal function (CREA) while diurnal variables were not. Furthermore, ABPM also predicted concomitant coronary heart disease whereas average office BP did not show such associations. ABPM identified patients at risk more efficiently than average office BP alone thereby documenting its advantages and overall utility to stratify disease severity and to predict ABPM in chronic renal disease P Jacob et al progression of renal disease in otherwise unselected patients with CRD. One of our study's main interest was to find ABP components that would help classify patients according to risk and renal prognosis, which would justify ABPM's practice. As a reference we used the mean value of 10 consecutive office BP measurements. Patients with CRD and hypertension frequently need adjustments of their antihypertensive medication. The treatment decision clearly depends on the precise knowledge of the individual blood pressure levels. Despite increasing evidence, however, international guidelines have not yet recommended the routine use of ABPM while they consider it only in a few circumstances, where diagnostic uncertainty should be ruled out. [10] [11] [12] [13] [14] [15] Patients experience ABPM as a stressful situation that imposes additional inconvenient visits at the clinic to return the monitor. Conversely, physicians are often forced to make rapid treatment decisions based on available clinical data. We compared two hypothetical situations, one where a single ABPM and one where average office BP readings alone were used to predict renal and cardiovascular outcome. Recent studies have suggested that the calculated average of consecutive office BP measurements strongly correlates with ABPM and may be used to predict outcome as well as ABPM thereby making ABPM largely unnecessary. 16, 17 Staessen et al, 3 for instance, investigated patients with essential hypertension and calculated the mean of two BP readings per monthly visit for a period of 3 months. In contrast, our office BP data represent a less scheduled series of follow-up visits reflecting more closely clinical routine practice.
About one half of our patients were normotensive according to ABPM while only one out of four patients was classified as normotensive based on average office BP, which consequently may overestimate BP. About 20% of the patients had resistant hypertension by definition. In a setting where all patients were treated for hypertension, the physicians obviously considered ABPM preferentially to rule out uncertainties about treatment efficacy and to facilitate treatment decisions in borderline cases. In our cohort, ABPM was clearly superior to average office BP values because of its association with renal disease progression and cardiovascular risk. In situations where a treatment decision or risk assessment need to be based on reliable BP information, ABPM might therefore be a useful additional test.
Interestingly, systolic but not diastolic ABP values correlated with CREA levels. The effect was independent of daytime. Furthermore, SBP and PP have been shown to be strongly associated with arterial stiffness and arteriosclerosis, a frequent problem in renal disease which concurs with our own findings where the presence of coronary artery disease was associated with high systolic ABP. 18 Finally, systolic ABP correlated with CREA in normotensive as well as in hypertensive patients. These effects were present despite antihypertensive treatment. Our study investigated renal disease and its progression. In their pivotal study, Clement et al 19 showed that ABPM was also capable of predicting new cardiovascular events in treated essential hypertensives after adjustment for traditional risk factors. UAE, in contrast, showed no consistent associations in our patients. Average UAE was 40.5 g/day and, therefore, most patients did not classify as microalbuminuric. Instead, the level of UAE indicated overt nephropathy while other factors and individual disease progression may have obscured the relation with BP results.
We used a conservative cutoff value at 140 mmHg to define normotension which was chosen for convenience and did not necessarily coincide with BP levels recommended for patients with CRD. 11, 13, 20 Such categorial limits, however, are primarily used by clinicians to check for hypertension and to decide on treatment. Our study identified uncon- trolled nocturnal systolic or mean arterial ABP as important and clinically relevant characteristics of patients at increased high risk for renal disease progression. These patients obviuously need revision of their antihypertensive treatment, close follow-up and attention towards concomitant cardiovascular disease. Uncontrolled nocturnal hypertension can easily be checked by ABPM while it appeared as a robust indicator also in treated patients. Day-time office BP readings do not provide information on nocturnal hypertension which underscores the necessity to evaluate nocturnal BP levels independently. Our observation adds further importance to recent studies where nocturnal BP behaviour was shown to predict subsequent morbidity. 4, 21 In contrast, the missing associations of diurnal ABP with cardiovascular risk in our cohort may relate to a greater diurnal BP variablitity caused by physical activity and the pharmacodynamics of day-time antihypertensive medication. In our cohort, the predictive power of ABPM concerning the dynamics of CREA was lost longitudinally. Any evaluation of risk and treatment decision, therefore, should be based on a recent ABPM not older than a few days or weeks depending on the purpose.
The results of our study were in line with other large community studies concerning essential hypertension. [22] [23] [24] Young et al, 25 for instance, analysed the control arm of the Systolic Hypertension in the Elderly Program (SHEP). Patients in the highest BP quartile had a significantly higher risk of declining kidney function than in the lowest BP quartile, independent of the type of BP component. Systolic BP showed the highest risk followed by MAP. Results from the Muliple Risk Factor Intervention Trial (MRFIT) indicate that the relative risk of endstage renal disease in men increases from 3.1 to 22.1 with increasing grades 1-4 of hypertension compared with normotension. 2 In our CRD patients diurnal systolic ABP and PP values showed similar associations.
Finally, the dipper status and the degree of BP dipping were not a strong predictor of baseline CREA or concomitant CHD. Dipping status, instead, was a strong predictor of declining renal function and, therefore, may be considered clinically. Studies by Timio et al and others 26, 27 found an increased risk of concomitant cardiovascular disease and a higher rate of progression towards renal failure in nonDIPs. Although the repeatability of circadian BP patterns has been reported to be poor and serial measurements are recommended to increase diagnostic reliability, we were able to confirm a similar association with renal disease progression based only on a single test. 28, 29 Our audit excluded repeated ABPM from analysis to obtain an unbiased picture of single ABPM. Furthermore, we did not aim at investigating the risk independently inherent with dipping status itself. The patients had been selected individually for ABPM by their attending physicians while the number in our cohort was relatively small. Our results therefore need to be confirmed by other studies. Nevertheless, we believe that our findings give valid information on the utility of ABPM in CRD.
In conclusion, our audit clearly showed that the current practice of ABPM in CRD provided clinically useful information to guide antihypertensive treatment. The information could not be obtained by serial office BP measurements alone. In particular, dipping status and uncontrolled nocturnal systolic hypertension were associated with a worse outcome and cardiovascular end-organ damage. Nocturnal hypertension can be easily detected by ABPM but escapes casual office BP readings. Physicians, therefore, might preferentially use ABPM in those CRD cases where nocturnal hypertension or a non-DIP pattern are already known, and where additional risk factors or a decline of renal function are present to check BP goals more comprehensively. Finally, our results suggest that ABPM may be useful when BP levels appear uncertain from office BP alone and a treatment decision should be made. ABPM results, therefore, should not be older than a few days. Future studies on the utility of ABPM will clearly have to investigate aspects of the clinical decision making process in more detail.
